Claudia Ferrara Koller

Characterization and prediction of positional 4-hydroxyproline and sulfotyrosine, two post-translational modifications that can occur at substantial levels in CHO cells-expressed biotherapeutics

M. Mølhøj, S. Klostermann, S. Nicolardi, 2019, mAbs.

Novel human IgG1 and IgG4 Fc-engineered antibodies with completely abolished immune effector functions.

C. Klein, Claudia Ferrara Koller, M. Kubbies, 2016, Protein engineering, design & selection : PEDS.

RG7386, a Novel Tetravalent FAP-DR5 Antibody, Effectively Triggers FAP-Dependent, Avidity-Driven DR5 Hyperclustering and Tumor Cell Apoptosis

C. Klein, B. Liu, K. Packman, 2016, Molecular Cancer Therapeutics.

RG6076 (CD19-4-1BBL): CD19-Targeted 4-1BB Ligand Combination with Glofitamab As an Off-the-Shelf, Enhanced T-Cell Redirection Therapy for B-Cell Malignancies

C. Klein, M. Bacac, Claudia Ferrara Koller, 2020 .